• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics Inc (NQ: CADL )

    5.950 +0.270 (+4.75%)
    Streaming Delayed Price Updated: 9:54 AM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Candel Therapeutics Inc

    < Previous 1 2 3 4 5 6 Next >
    CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
    Candel Therapeutics just reported results for the second quarter of 2024. 
    Via InvestorPlace
    Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
    GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
    Via Benzinga
    Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Looking Into Candel Therapeutics's Recent Short Interest
    Via Benzinga
    How Is The Market Feeling About Candel Therapeutics?
    Via Benzinga
    Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
    Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments 
    Via News Direct
    7 A-Rated Biotech Stocks Worth Betting on in June
    A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
    Via InvestorPlace
    Why BioRestorative Therapies Stock Is Moving Higher Thursday
    BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic... 
    Via Benzinga
    Candel Therapeutics to Join Russell 3000® Index
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
    --News Direct-- 
    Via News Direct
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
    By Jeremy Golden, Benzinga 
    Via TheNewswire.com
    Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
    Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer 
    Via News Direct
    FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
    From Candel Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
    Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC 
    From Candel Therapeutics
    Via GlobeNewswire
    NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
    Candel Therapeutics just reported results for the first quarter of 2024. 
    Via InvestorPlace
    Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Candel Therapeutics Stock?
    Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently... 
    Via Benzinga
    Exposures Product Safety
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.